Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Dec;66(6):1109–1115. doi: 10.1038/bjc.1992.419

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

S Y Loh 1, P Mistry 1, L R Kelland 1, G Abel 1, K R Harrap 1
PMCID: PMC1978040  PMID: 1457352

Abstract

Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro in the 41M human ovarian carcinoma cell line, established from a previously untreated patient. Three cisplatin-resistant variants were selected at approximately 2, 4 and 6-fold resistance (in terms of 50% inhibitory concentrations), in order to study the underlying mechanisms of acquired cisplatin resistance. Compared to the parent line, platinum accumulation following exposure to equimolar concentrations of cisplatin was on average (across the entire concentration range) 2.9, 3.6 and 4.8-fold lower in the 41McisR2, 41McisR4 and 41McisR6 cell lines, respectively. Thus the difference in uptake corresponded closely with their resistance factor in the three resistant variants. Moreover, a significant reduction in platinum accumulation was observed as early as 5 min after exposure to cisplatin in the 41M vs 41McisR6 cell lines. Platinum accumulation was similar in all cell lines following exposure to equitoxic concentrations (2 h IC50) of cisplatin. Enhanced efflux of drug was not observed between the 41M and 41McisR6 cells. In addition, there was no difference in intracellular glutathione (GSH) levels. Our previous studies have shown no indication of metallothionein involvement and the decrease in cisplatin uptake in the 41McisR6 cells was reflected by a similar reduction in DNA interstrand cross-links (ISC) formation. These results suggest that the mechanism of acquired resistance to cisplatin in the 41McisR6 cell line may be predominantly due to reduced drug uptake. The 41McisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium adenosine triphosphatase (Na+, K(+)-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na+, K(+)-ATPase levels, and Na+ potential across the plasma membrane. Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examined. The data suggests that increased accumulation of these compounds, as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.

Full text

PDF
1109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  2. Andrews P. A., Jones J. A., Varki N. M., Howell S. B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun. 1990;2(2):93–100. doi: 10.3727/095535490820874641. [DOI] [PubMed] [Google Scholar]
  3. Andrews P. A., Mann S. C., Huynh H. H., Albright K. D. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res. 1991 Jul 15;51(14):3677–3681. [PubMed] [Google Scholar]
  4. Andrews P. A., Murphy M. P., Howell S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985 Dec;45(12 Pt 1):6250–6253. [PubMed] [Google Scholar]
  5. Andrews P. A., Velury S., Mann S. C., Howell S. B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988 Jan 1;48(1):68–73. [PubMed] [Google Scholar]
  6. Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224–4232. [PubMed] [Google Scholar]
  7. Bernal S. D., Speak J. A., Boeheim K., Dreyfuss A. I., Wright J. E., Teicher B. A., Rosowsky A., Tsao S. W., Wong Y. C. Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem. 1990 Jun 1;95(1):61–70. doi: 10.1007/BF00219531. [DOI] [PubMed] [Google Scholar]
  8. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Harrap K. R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985 Sep;12 (Suppl A):51–57. doi: 10.1016/0305-7372(85)90018-0. [DOI] [PubMed] [Google Scholar]
  9. Eichholtz-Wirth H., Hietel B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer. 1986 Aug;54(2):239–243. doi: 10.1038/bjc.1986.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Green J. A., Vistica D. T., Young R. C., Hamilton T. C., Rogan A. M., Ozols R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984 Nov;44(11):5427–5431. [PubMed] [Google Scholar]
  11. Harrap K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev. 1985 Sep;12 (Suppl A):21–33. doi: 10.1016/0305-7372(85)90015-5. [DOI] [PubMed] [Google Scholar]
  12. Hecquet B., Leroy A., Lefebvre J. L., Peyrat J. P., Adenis L. Uptake of platinum compounds in human tumors. In vitro study. Bull Cancer. 1986;73(5):535–541. [PubMed] [Google Scholar]
  13. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hospers G. A., Mulder N. H., de Jong B., de Ley L., Uges D. R., Fichtinger-Schepman A. M., Scheper R. J., de Vries E. G. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res. 1988 Dec 1;48(23):6803–6807. [PubMed] [Google Scholar]
  15. Hromas R. A., North J. A., Burns C. P. Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett. 1987 Aug;36(2):197–201. doi: 10.1016/0304-3835(87)90091-7. [DOI] [PubMed] [Google Scholar]
  16. Kawai K., Kamatani N., Georges E., Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem. 1990 Aug 5;265(22):13137–13142. [PubMed] [Google Scholar]
  17. Kawai K., Kamatani N., Kuroshima S., Nobori T., Nishioka K., Kamiya H., Sakurai M., Mikanagi K. Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-dichlorodiammineplatinum(II) resistance. Cancer Lett. 1987 May;35(2):147–152. doi: 10.1016/0304-3835(87)90038-3. [DOI] [PubMed] [Google Scholar]
  18. Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
  19. Kelland L. R., Murrer B. A., Abel G., Giandomenico C. M., Mistry P., Harrap K. R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1992 Feb 15;52(4):822–828. [PubMed] [Google Scholar]
  20. Kikuchi Y., Iwano I., Miyauchi M., Sasa H., Nagata I., Kuki E. Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 1990 Nov;39(2):199–203. doi: 10.1016/0090-8258(90)90432-k. [DOI] [PubMed] [Google Scholar]
  21. Kraker A. J., Moore C. W. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. 1988 Jan 1;48(1):9–13. [PubMed] [Google Scholar]
  22. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  23. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  24. Louie K. G., Behrens B. C., Kinsella T. J., Hamilton T. C., Grotzinger K. R., McKoy W. M., Winker M. A., Ozols R. F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985 May;45(5):2110–2115. [PubMed] [Google Scholar]
  25. Mann S. C., Andrews P. A., Howell S. B. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1990;25(4):236–240. doi: 10.1007/BF00684878. [DOI] [PubMed] [Google Scholar]
  26. Metcalfe S. A., Cain K., Hill B. T. Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett. 1986 May;31(2):163–169. doi: 10.1016/0304-3835(86)90007-8. [DOI] [PubMed] [Google Scholar]
  27. Mistry P., Kelland L. R., Abel G., Sidhar S., Harrap K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 1991 Aug;64(2):215–220. doi: 10.1038/bjc.1991.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Morikage T., Bungo M., Inomata M., Yoshida M., Ohmori T., Fujiwara Y., Nishio K., Saijo N. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res. 1991 Jun;82(6):747–751. doi: 10.1111/j.1349-7006.1991.tb01912.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ozols R. F., Young R. C. Chemotherapy of ovarian cancer. Semin Oncol. 1984 Sep;11(3):251–263. [PubMed] [Google Scholar]
  30. Richon V. M., Schulte N., Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 1987 Apr 15;47(8):2056–2061. [PubMed] [Google Scholar]
  31. Teicher B. A., Holden S. A., Kelley M. J., Shea T. C., Cucchi C. A., Rosowsky A., Henner W. D., Frei E., 3rd Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987 Jan 15;47(2):388–393. [PubMed] [Google Scholar]
  32. Waud W. R. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res. 1987 Dec 15;47(24 Pt 1):6549–6555. [PubMed] [Google Scholar]
  33. de Graeff A., Slebos R. J., Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol. 1988;22(4):325–332. doi: 10.1007/BF00254240. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES